Tsai T W, Freytes C O
Division of Hematology/Oncology, University of Texas Health Science Center at San Antonio, USA.
Adv Intern Med. 1997;42:423-51.
Bone marrow transplantation is the only curative treatment in adult patients with AML who fail to attain a complete remission or who experience a relapse. Unfortunately, the median age for patients with AML is estimated to be 62 years, which precludes allogeneic BMT for a significant number of patients with AML. For patients with relapsed AML who lack an HLA-identical donor or who are too old to undergo allogeneic BMT, autologous BMT should be considered since current standard salvage chemotherapy regimens do not produce durable remissions in the overwhelming majority of patients. The role of allogeneic and autologous BMT was initial postremission therapy is controversial. Ongoing studies may define the optimal postremission therapy for adult patients with AML in first remission.
对于未能获得完全缓解或复发的成年急性髓系白血病（AML）患者，骨髓移植是唯一的治愈性治疗方法。不幸的是，AML患者的中位年龄估计为62岁，这使得大量AML患者无法进行异基因骨髓移植。对于复发的AML患者，如果缺乏HLA匹配的供体或年龄太大而无法进行异基因骨髓移植，应考虑自体骨髓移植，因为目前标准的挽救性化疗方案在绝大多数患者中无法产生持久缓解。异基因和自体骨髓移植作为缓解后初始治疗的作用存在争议。正在进行的研究可能会确定首次缓解的成年AML患者的最佳缓解后治疗方案。
